

Table S2. Survival outcomes of patients with pT1N0M0 breast cancer

Outcome	Patients with HR+/HER2- BC (n=987)		Patients with HR+/HER2+ BC (n=218)		Patients with HR- /HER2+ BC (n=187)		Patients with HR- /HER2- BC (n=341)	
	5-year rate, % (95% CI)	10-year rate, % (95% CI)	5-year rate, % (95% CI)	10-year rate, % (95% CI)	5-year rate, % (95% CI)	10-year rate, % (95% CI)	5-year rate, % (95% CI)	10-year rate, % (95% CI)
DFS	92.1 (90.2-93.6)	84.0 (81.4-86.3)	83.5 (77.9-87.8)	80.3 (74.4-85.0)	79.1 (72.5-84.3)	73.4 (66.2-79.3)	87.3 (83.3-90.1)	78.8 (73.9-82.9)
DRFS	94.6 (93.0-95.8)	89.1 (86.8-91.0)	83.9 (78.3-88.2)	81.1 (75.2-85.7)	84.0 (77.9-88.5)	76.0 (68.9-81.7)	90.3 (86.6-93.0)	85.5 (81.2-88.9)
BCSS	98.1 (97.0-98.8)	93.6 (91.7-95.1)	95.9 (92.2-97.9)	85.5 (79.8-90.1)	92.0 (87.1-95.1)	83.8 (77.5-88.5)	94.6 (91.6-96.5)	88.6 (84.5-91.7)
OS	97.5 (96.3-98.3)	91.1 (89.0-92.8)	95.9 (92.2-97.9)	85.5 (79.8-89.7)	92.0 (87.1-95.1)	81.8 (75.2-86.8)	92.1 (88.7-94.5)	83.4 (78.8-87.1)

Abbreviations: HR, hormone receptor; HER2, human epidermal growth factor receptor 2; CI, confidence interval, DFS, Disease-Free Survival; DRFS, Distant Recurrence-Free Survival, BCSS; Breast Cancer-Specific Survival; OS, Overall Survival.